What is Bicara Therapeutics's stock-based comp?

Bicara Therapeutics (BCAX) reported stock-based comp of $178K in Q4 2025.

What does stock-based comp mean?

This metric quantifies the dollar value of share-based compensation that is treated as a non-deductible expense for income tax purposes. It reflects the difference between accounting expense and tax-deductible amounts for equity awards. This helps investors reconcile the gap between book income and taxable income.

Bicara Therapeutics BCAX Stock-Based Comp

Stock-Based Comp at other companies

Target HospitalityTH

$480.25K+171%

Proto LabsPRLB

$76K—

ePlusPLUS

$608.5K+20.5%

Trex CompanyTREX

$25K+113%

TidewaterTDW

$828.25K—

Healthcare Services GroupHCSG

2.7%-0.6pp

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost.

The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's stock-based comp?: Bicara Therapeutics (BCAX) reported stock-based comp of $178K in Q4 2025.
What does stock-based comp mean?: This metric quantifies the dollar value of share-based compensation that is treated as a non-deductible expense for income tax purposes. It reflects the difference between accounting expense and tax-deductible amounts for equity awards. This helps investors reconcile the gap between book income and taxable income.